12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
<p><strong>Background</p></strong> While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric events have emerged. More data are therefore needed to assess the effects of se...
Main Authors: | De Giorgi, R, Koychev, I, Adler, A, Cowen, P, Harmer, C, Harrison, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2024
|
Similar Items
-
Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis
by: Mahmoud Balata, et al.
Published: (2024-10-01) -
Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data
by: Takeshi Horii, et al.
Published: (2024-11-01) -
Six-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19
by: Taquet, M, et al.
Published: (2021) -
Why Propensity Scores Should Not Be Used for Matching
by: King, Gary, et al.
Published: (2020) -
Propensity-score matching: a clinician’s guide
by: Andrew D Althouse
Published: (2016-06-01)